XRAY Strangle Strategy
XRAY (DENTSPLY SIRONA Inc.), in the Healthcare sector, (Medical - Instruments & Supplies industry), listed on NASDAQ.
DENTSPLY SIRONA Inc. manufactures and sells various dental products and technologies for professional dental market worldwide. The company operates through two segments, Technologies & Equipment, and Consumables. The Technologies & Equipment segment provides dental equipment, such as treatment centers, imaging equipment, motorized dental handpieces, and other instruments for dental practitioners and specialists; dental CAD/CAM technologies for dental offices to support various digital dental procedures, including dental restorations; dentist-directed clear aligner solutions, SureSmile, and direct-to-consumer clear aligner solutions, as well as high frequency vibration technology device; implants; and urology catheters and other healthcare-related consumable products. The Consumables segment offers endodontic products comprising drills, filers, sealers, irrigation needles, and other tools or single-use solutions, which support root canal procedures; restorative products that include artificial teeth, dental ceramics, digital dentures, precious metal dental alloys, and crown and bridge porcelain products. It also provides small equipment products, which comprise intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers, as well as dental anesthetics, prophylaxis paste, dental sealants, impression materials, teeth whiteners, and topical fluoride. The company was founded in 1877 and is headquartered in Charlotte, North Carolina.
XRAY (DENTSPLY SIRONA Inc.) trades in the Healthcare sector, specifically Medical - Instruments & Supplies, with a market capitalization of approximately $2.09B, a beta of 0.94 versus the broader market, a 52-week range of 9.85-17.09, average daily share volume of 4.7M, a public-listing history dating back to 1987, approximately 14K full-time employees. These structural characteristics shape how XRAY stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.94 places XRAY roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline. XRAY pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.
What is a strangle on XRAY?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current XRAY snapshot
As of May 15, 2026, spot at $10.04, ATM IV 48.70%, IV rank 15.93%, expected move 13.96%. The strangle on XRAY below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on XRAY specifically: XRAY IV at 48.70% is on the cheap side of its 1-year range, which favors premium-buying structures like a XRAY strangle, with a market-implied 1-standard-deviation move of approximately 13.96% (roughly $1.40 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated XRAY expiries trade a higher absolute premium for lower per-day decay. Position sizing on XRAY should anchor to the underlying notional of $10.04 per share and to the trader's directional view on XRAY stock.
XRAY strangle setup
The XRAY strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With XRAY near $10.04, the first option leg uses a $10.54 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed XRAY chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 XRAY shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $10.54 | N/A |
| Buy 1 | Put | $9.54 | N/A |
XRAY strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
XRAY strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on XRAY. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on XRAY
Strangles on XRAY are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the XRAY chain.
XRAY thesis for this strangle
The market-implied 1-standard-deviation range for XRAY extends from approximately $8.64 on the downside to $11.44 on the upside. A XRAY long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current XRAY IV rank near 15.93% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on XRAY at 48.70%. As a Healthcare name, XRAY options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to XRAY-specific events.
XRAY strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. XRAY positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move XRAY alongside the broader basket even when XRAY-specific fundamentals are unchanged. Always rebuild the position from current XRAY chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on XRAY?
- A strangle on XRAY is the strangle strategy applied to XRAY (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With XRAY stock trading near $10.04, the strikes shown on this page are snapped to the nearest listed XRAY chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are XRAY strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the XRAY strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 48.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a XRAY strangle?
- The breakeven for the XRAY strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current XRAY market-implied 1-standard-deviation expected move is approximately 13.96%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on XRAY?
- Strangles on XRAY are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the XRAY chain.
- How does current XRAY implied volatility affect this strangle?
- XRAY ATM IV is at 48.70% with IV rank near 15.93%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.